Latest news with #JiangsuHengRui
Globe and Mail
15-05-2025
- Health
- Globe and Mail
Non-Cystic Fibrosis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the Non-Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Non-Cystic Fibrosis Bronchiectasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Cystic Fibrosis Bronchiectasis Pipeline Outlook Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis. In May 2025, Genentech Inc. conducted a study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in patients with muco-obstructive disease. DelveInsight's Non-Cystic Fibrosis Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non-Cystic Fibrosis Bronchiectasis treatment. The leading Non-Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others. Promising Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, Ciprofloxacin DPI (BAYQ3939) and others. Stay ahead with the most recent pipeline outlook for Non-Cystic Fibrosis Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Cystic Fibrosis Bronchiectasis Treatment Drugs Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Profile Brensocatib: Insmed Incorporated Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. HSK31858: Haisco Pharmaceutical Group Co., Ltd. HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly. CSL 787: CSL Behring CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non‐cystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis. The Non-Cystic Fibrosis Bronchiectasis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment. Non-Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market Explore groundbreaking therapies and clinical trials in the Non-Cystic Fibrosis Bronchiectasis Pipeline. Access DelveInsight's detailed report now! @ New Non-Cystic Fibrosis Bronchiectasis Drugs Non-Cystic Fibrosis Bronchiectasis Companies Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others. Non‐cystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Unveil the future of Non-Cystic Fibrosis Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report Coverage- Global Non-Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, Ciprofloxacin DPI (BAYQ3939) and others. Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Non-Cystic Fibrosis Bronchiectasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Cystic Fibrosis Bronchiectasis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Non‐cystic fibrosis bronchiectasis: Overview Pipeline Therapeutics Therapeutic Assessment Non‐cystic fibrosis bronchiectasis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Brensocatib: Insmed Incorporated Drug profiles in the detailed report….. Mid Stage Products (Phase II) HSK31858: Haisco Pharmaceutical Group Co., Ltd. Drug profiles in the detailed report….. Early Stage Products (Phase I) CSL 787: CSL Behring Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Non‐cystic fibrosis bronchiectasis Key Companies Non‐cystic fibrosis bronchiectasis Key Products Non‐cystic fibrosis bronchiectasis- Unmet Needs Non‐cystic fibrosis bronchiectasis- Market Drivers and Barriers Non‐cystic fibrosis bronchiectasis- Future Perspectives and Conclusion Non‐cystic fibrosis bronchiectasis Analyst Views Non‐cystic fibrosis bronchiectasis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
15-05-2025
- Health
- Globe and Mail
Bronchiectasis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Bronchiectasis Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including Bronchiectasis clinical trials and nonclinical stage products. It also covers the Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Bronchiectasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Bronchiectasis Pipeline Outlook Key Takeaways from Bronchiectasis Pipeline Report In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis. In May 2025, Genentech Inc. announced a phase I study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-Obstructive Disease. In May 2025, Mannkind Corporation conducted a phase 3 study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection. DelveInsight's Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment. The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others. Promising Bronchiectasis Pipeline Therapies such as Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others. Stay ahead with the most recent pipeline outlook for Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bronchiectasis Treatment Drugs Bronchiectasis Emerging Drugs Profile Benralizumab: AstraZeneca Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis. S1226: SolAeroMed S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the ß-adrenergic agonists and thus complements, rather than replaces, existing treatments. Brensocatib: Insmed Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. The Bronchiectasis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment. Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market Explore groundbreaking therapies and clinical trials in the Bronchiectasis Pipeline. Access DelveInsight's detailed report now! @ New Bronchiectasis Drugs Pulmonary Fibrosis Companies AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others. Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Bronchiectasis Products have been categorized under various Molecule types such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Unveil the future of Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers Scope of the Bronchiectasis Pipeline Report Coverage- Global Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others. Bronchiectasis Pipeline Therapies- Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others. Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Bronchiectasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Bronchiectasis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Bronchiectasis: Overview Pipeline Therapeutics Therapeutic Assessment Bronchiectasis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Benralizumab: AstraZeneca Drug profiles in the detailed report….. Mid Stage Products (Phase II) S1226: SolAeroMed Drug profiles in the detailed report….. Early Stage Products (Phase I) CSL787: CSL Behring Drug profiles in the detailed report….. Preclinical and Discovery Stage Products AP-PA02: Armata Pharmaceuticals Drug profiles in the detailed report….. Inactive Products Bronchiectasis Key Companies Bronchiectasis Key Products Bronchiectasis- Unmet Needs Bronchiectasis- Market Drivers and Barriers Bronchiectasis- Future Perspectives and Conclusion Bronchiectasis Analyst Views Bronchiectasis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
